

## ASX Announcement

# Anti-Infective Research Unit Established at Murdoch Children's Research Institute

### Highlights:

- Recce's new Anti-Infective Research Unit located within Murdoch Children's world-leading research facilities - internationally recognised for medical research breakthroughs
- Fit-for-purpose laboratory space will be allocated solely to this work within Murdoch Children's - one of the top three children's research institutes worldwide
- Dedicated Murdoch Children's team with access to infectious disease and other expertise together with \$ millions in specialist infrastructure to support Recce's expanding anti-infective pipeline
- Recce will streamline ongoing pre-clinical programs and explore new research development opportunities
- Subsidised collaborative for tackling infectious diseases – cost-efficient studies, laboratory space provided at no additional cost

**SYDNEY Australia, 15 December 2022:** Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (the **Company**), the Company developing a New Class of Synthetic Anti-infectives, today announced the commencement of an *Anti-Infective Research (AIR)* Unit through the execution of a research collaboration agreement with Murdoch Children's Research Institute (Murdoch Children's), securing a dedicated Murdoch Children's research team of infectious disease experts, fit-for-purpose laboratory space access to a library of clinical isolates and drug-resistant pathogens.

Securing this research space supports Recce's expanding pre-clinical programs, with world-leading infectious disease researchers dedicating their efforts to a suite of pre-clinical studies investigating the antimicrobial activity of RECCE® compounds. The programs continue to be led by Dr Phil Sutton, former Head of Murdoch Children's Mucosal Immunology and Recce's Vice President of Translational Sciences (announced 11 July 2022).



**ASX:** RCE, **FSE:** R9Q

**Head Office:** Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 **T** +61 (02) 9256 2571

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Dr Sutton said, “We are thrilled by this agreement with Murdoch Children's, as it will give Recce direct access to critical pre-clinical laboratory studies. Access to the facilities within one of the world's leading research institutes will also allow us to draw upon their impressive resources

and clinical expertise.”

The Company's work with Murdoch Children's has already played a pivotal role in the delivery of results surrounding ongoing pre-clinical programs, generating R327 data demonstrating strong bactericidal activity against a range of deadly pathogens.

The planned research activities conducted in Recce's AIR Unit will have a particular focus in advancing the Company's Bacterial Sinusitis program, *Mycobacterium abscessus* program, and more with all intellectual property rights and results owned by the Company.

### Recce's Pipeline

Asset and Route of Administration	Indications	Discovery	Pre-Clinical	Phase I	Phase II	Phase III
R327 Intravenous*	Serious/life threatening bacterial infections including sepsis					
	Urinary tract infections including urosepsis					
	Multidose, early-stage sepsis efficacy study					
R327 Topical*	Wound infections including infected burns					
	Diabetic Foot Ulcers					
RCE Compounds*	<i>Mycobacterium abscessus</i> pre-clinical program	Programs undertaken by Recce's AIR Unit				
	Bacterial Sinusitis pre-clinical program					
	Additional TBA pre-clinical programs					

Murdoch Children's Research Institute is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact. Based in Melbourne, one of the world's most innovative cities for world-leading medical research and development, the dedicated research within Recce's AIR Unit will streamline ongoing pre-clinical programs and explore new research development opportunities.



#### Chief Executive Officer

James Graham  
Recce Pharmaceuticals Ltd  
+61 (02) 9256 2571  
james.graham@recce.com.au

#### Media and Investor Relations (AU)

Andrew Geddes  
CityPR  
+61 (02) 9267 4511  
ageddes@citypublicrelations.com.au

#### Media and Investor Relations (USA)

Jordyn Temperato  
LifeSci Communications  
jtemperato@lifescicomms.com

**recce.com.au**  
ACN 124 849 065

Recce Pharmaceuticals Chief Executive Officer James Graham said, “With access to Murdoch Children's world-leading facilities, this agreement will further advance our pre-clinical programs. We are delighted to collaborate with Murdoch Children's in addressing unmet medical needs and look forward to advancing anti-infective research.”

This announcement has been approved for release by Recce Pharmaceuticals Board.



#### Chief Executive Officer

**James Graham**  
Recce Pharmaceuticals Ltd  
+61 (02) 9256 2571  
[james.graham@recce.com.au](mailto:james.graham@recce.com.au)

#### Media and Investor Relations (AU)

**Andrew Geddes**  
CityPR  
+61 (02) 9267 4511  
[ageddes@citypublicrelations.com.au](mailto:ageddes@citypublicrelations.com.au)

#### Media and Investor Relations (USA)

**Jordyn Temperato**  
LifeSci Communications  
[jtemperato@lifescicomms.com](mailto:jtemperato@lifescicomms.com)

**[recce.com.au](http://recce.com.au)**  
ACN 124 849 065

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.



### Chief Executive Officer

James Graham  
Recce Pharmaceuticals Ltd  
+61 (02) 9256 2571  
james.graham@recce.com.au

### Media and Investor Relations (AU)

Andrew Geddes  
CityPR  
+61 (02) 9267 4511  
ageddes@citypublicrelations.com.au

### Media and Investor Relations (USA)

Jordyn Temperato  
LifeSci Communications  
jtemperato@lifescicomms.com

**recce.com.au**  
ACN 124 849 065